As FDA Suicidality Reviews Become More Common, Firms Move Into C-CASA
FDA's review of anticonvulsant drugs for suicidality risks suggests that firms should reevaluate their clinical development strategies to anticipate a growing need for such data
FDA's review of anticonvulsant drugs for suicidality risks suggests that firms should reevaluate their clinical development strategies to anticipate a growing need for such data